- Home
- NCTY vs STRO Comparison
NCTY vs STRO Comparison
Compare NCTY & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCTY
- STRO
- Stock Information
- Founded
- NCTY 1999
- STRO 2003
- Country
- NCTY China
- STRO United States
- Employees
- NCTY N/A
- STRO N/A
- Industry
- NCTY Business Services
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCTY Consumer Discretionary
- STRO Health Care
- Exchange
- NCTY Nasdaq
- STRO Nasdaq
- Market Cap
- NCTY 148.0M
- STRO 147.6M
- IPO Year
- NCTY 2004
- STRO 2018
- Fundamental
- Price
- NCTY $14.17
- STRO $0.74
- Analyst Decision
- NCTY
- STRO Buy
- Analyst Count
- NCTY 0
- STRO 7
- Target Price
- NCTY N/A
- STRO $6.83
- AVG Volume (30 Days)
- NCTY 64.3K
- STRO 2.2M
- Earning Date
- NCTY 01-01-0001
- STRO 03-13-2025
- Dividend Yield
- NCTY N/A
- STRO N/A
- EPS Growth
- NCTY N/A
- STRO N/A
- EPS
- NCTY 9.91
- STRO N/A
- Revenue
- NCTY $24,286,983.00
- STRO $62,043,000.00
- Revenue This Year
- NCTY N/A
- STRO N/A
- Revenue Next Year
- NCTY N/A
- STRO N/A
- P/E Ratio
- NCTY $3.24
- STRO N/A
- Revenue Growth
- NCTY 2.82
- STRO N/A
- 52 Week Low
- NCTY $4.90
- STRO $0.72
- 52 Week High
- NCTY $20.59
- STRO $5.88
- Technical
- Relative Strength Index (RSI)
- NCTY 55.50
- STRO 26.77
- Support Level
- NCTY $12.58
- STRO $0.72
- Resistance Level
- NCTY $12.02
- STRO $0.80
- Average True Range (ATR)
- NCTY 0.81
- STRO 0.10
- MACD
- NCTY 0.40
- STRO -0.01
- Stochastic Oscillator
- NCTY 67.49
- STRO 5.68
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China and other areas.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.